MannKind stock adds an inhaled GLP-1 licensing deal

Published on 09/29/2026 at 20:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MannKind stock gets a new inhaled GLP-1 collaboration dated September 9, 2026. Q2 revenue reached USD 109.37 million, up 43.00 percent year over year.

MNKD, US5638651064, Illustration mit AI erstellt.

MannKind Corporation (ISIN US5638651064) reported USD 109.37 million in second-quarter revenue for the period ended June 30, 2026, up 43.00 percent from USD 76.53 million a year earlier. The company is also expanding its inhaled-drug platform through a September 9, 2026 licensing agreement with Rose Pharma.

GLP-1 deal expands the platform

According to MannKind on September 9, 2026, the companies will develop ROSE-010 Technosphere, an investigational rapid-acting, short-duration GLP-1 therapy for weight management. Rose Pharma received an exclusive worldwide license to use MannKind's Technosphere technology for the program.

MannKind will provide formulation development, pharmaceutical development and manufacturing support through completion of a Phase 1b study. In return, the company will receive an equity interest in Rose Pharma, potential royalties on future net sales and representation on Rose Pharma's board.

Revenue grows while losses persist

The latest quarter shows the commercial opportunity and the financial challenge together. According to The Globe and Mail in a September 12, 2026 item, MannKind posted a GAAP net loss of USD 19.03 million for the quarter, compared with a net profit of USD 0.67 million in the prior-year period.

The same report said Cantor Fitzgerald maintained a Buy rating and a USD 8.00 price target. That target is more than double the USD 3.35 Nasdaq quote available on September 29, 2026, but the company remains loss-making on the latest reported quarter.

Nasdaq quote and valuation

MannKind was trading at USD 3.35 on Nasdaq at 2:00 p.m. ET on September 29, 2026. The company had a market capitalization of USD 1.1 billion on that date, while its 52-week range was USD 2.23 to USD 6.51.